Psychosocial support for caregivers of bone marrow transplant patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of a psychosocial intervention called BMT-CARE aimed at improving the quality of life and reducing distress among caregivers of patients undergoing hematopoietic cell transplant (HCT). Participants will be randomly assigned to receive either the BMT-CARE intervention along with usual care or just the usual care. The study will involve approximately 400 caregivers and 400 patients, with participation lasting up to 180 days post-transplant. The research is supported by the National Institutes of Health and aims to identify barriers and facilitators for implementing the BMT-CARE intervention.

Why it matters

Who can join: the full rules

Caregiver Inclusion Criteria:

* Adult caregivers (≥18 years) relative or friend of a patient identified as living with them or having in-person contact with them at least twice a week.
* Caregiver of a patient receiving allogeneic or autologous HCT for the treatment of cancer.
* Ability to read and respond to survey questions in English, Spanish or with minimal assistance from an interpreter.

Caregiver Exclusion Criteria:

* Caregivers of patients undergoing HCT for a benign hematologic condition or undergoing outpatient HCT.
* Caregivers with a major untreated psychiatric or cognitive condition which the treating oncology clinicians believes interferes with the capacity to provide informed consent.
* Caregivers of patients who have already undergone HCT within the past 5 years

Patient Inclusion Criteria:

* Adult patients (≥18 years) with a hematologic malignancy and planned admission for autologous or allogeneic HCT.
* Ability to respond to questions in English, Spanish, or with minimal assistance from an interpreter.

Where it's running

• University of Alabama at Brimingham
  Birmingham, Alabama, United States Recruiting
• Moffitt Cancer Center
  Tampa, Florida, United States Recruiting
• Massachusetts General Hospital Cancer Center
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Areej El-Jawahri, MD — Massachusetts General Hospital
• Study coordinator: Areej El-Jawahri, MD
• Email: ael-jawahri@mgb.org
• Phone: 617-721-4000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating the role of genetics in kidney disease progression

  This study is trying to see how genetics affects the worsening of kidney diseases like acute kidney injury and chronic kidney disease in people, especially those with high blood pressure.

  Recruiting Ospedale San Raffaele · Milan · NCT06416761

• High-dose vs standard-dose flu vaccine in adults with blood cancers on B-cell-depleting therapy

  This study tests whether a high-dose flu shot evokes a stronger immune response than a standard-dose shot in adults with hematologic cancers who recently had B-cell-depleting therapy.

  Recruiting Phase 2 Asan Medical Center · Seoul · NCT07926217

• CD45RA-depleted donor cells to help fight stubborn viral infections after haploidentical transplant

  This trial tests whether giving patients specially prepared donor immune cells (CD45RA-depleted DLI) can help clear viral infections that linger after a stem cell transplant and who have not fully recovered their immunity.

  Recruiting Phase 1/2 Ruijin Hospital · Shanghai, SH · NCT07662369

• Identifying biomarkers for CAR-T cell therapy in cancer patients

  This study looks at real-world CAR-T therapy in adults with blood cancers to see which biomarkers predict who responds or relapses.

  Recruiting University Hospital, Lille · Lille and 1 other locations · NCT07609485

• QH101 Vδ2 T-cell therapy for adults with relapsed or advanced malignant tumors

  This study will try QH101, an off-the-shelf Vδ2 T-cell therapy, in adults with relapsed or advanced blood cancers or solid tumors to see if it is safe and helps fight tumors.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07570563

• Short versus long maribavir treatment after allogeneic stem cell transplant

  This trial tests whether a shorter or longer course of maribavir helps adults with refractory CMV infection after their first allogeneic stem cell transplant.

  Recruiting Phase 3 Ruijin Hospital · Shanghai · NCT07511127

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.